Clinical Differences in Patients Infected with Fusobacterium and Antimicrobial Susceptibility of Fusobacterium Isolates Recovered at a Tertiary-Care Hospital in Korea
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Fusobacterium species are obligately anaerobic, gram-negative bacilli. Especially, F. nucleatum and F. necrophorum are highly relevant human pathogens. We investigated clinical differences in patients infected with Fusobacterium spp. and determined the antimicrobial susceptibility of Fusobacterium isolates. Methods: We collected clinical data of 86 patients from whom Fusobacterium spp. were isolated from clinical specimens at a tertiary-care hospital in Korea between 2003 and 2020. In total, 76 non-duplicated Fusobacterium isolates were selected for antimicrobial susceptibility testing by the agar dilution method, according to the Clinical and Laboratory Standards Institute guidelines (M11-A9). Results: F. nucleatum was most frequently isolated from blood cultures and was associated with hematologic malignancy, whereas F. necrophorum was mostly prevalent in head and neck infections. Anti-anaerobic agents were more commonly used to treat F. nucleatum and F. varium infections than to treat F. necrophorum infections. We observed no significant difference in mortality between patients infected with these species. All F. nucleatum and F. necrophorum isolates were susceptible to the antimicrobial agents tested. F. varium was resistant to clindamycin (48%) and moxifloxacin (24%), and F. mortiferum was resistant to penicillin G (22%) and ceftriaxone (67%). β-Lactamase activity was not detected. Conclusions: Despite the clinical differences among patients with clinically important Fusobacterium infections, there was no significant difference in the mortality rates. Some Fusobacterium spp. were resistant to penicillin G, ceftriaxone, clindamycin, or moxifloxacin. This study may provide clinically relevant data for implementing empirical treatment against Fusobacterium infections.
Abstract
Background: Fusobacterium species are obligately anaerobic, gram-negative bacilli. Especially, F. nucleatum and F. necrophorum are highly relevant human pathogens. We investigated clinical differences in patients infected with Fusobacterium spp. and determined the antimicrobial susceptibility of Fusobacterium isolates. Methods: We collected clinical data of 86 patients from whom Fusobacterium spp. were isolated from clinical specimens at a tertiary-care hospital in Korea between 2003 and 2020. In total, 76 non-duplicated Fusobacterium isolates were selected for antimicrobial susceptibility testing by the agar dilution method, according to the Clinical and Laboratory Standards Institute guidelines (M11-A9). Results: F. nucleatum was most frequently isolated from blood cultures and was associated with hematologic malignancy, whereas F. necrophorum was mostly prevalent in head and neck infections. Anti-anaerobic agents were more commonly used to treat F. nucleatum and F. varium infections than to treat F. necrophorum infections. We observed no significant difference in mortality between patients infected with these species. All F. nucleatum and F. necrophorum isolates were susceptible to the antimicrobial agents tested. F. varium was resistant to clindamycin (48%) and moxifloxacin (24%), and F. mortiferum was resistant to penicillin G (22%) and ceftriaxone (67%). β-Lactamase activity was not detected. Conclusions: Despite the clinical differences among patients with clinically important Fusobacterium infections, there was no significant difference in the mortality rates. Some Fusobacterium spp. were resistant to penicillin G, ceftriaxone, clindamycin, or moxifloxacin. This study may provide clinically relevant data for implementing empirical treatment against Fusobacterium infections.
참고문헌 (37)
- Jorgensen JH, "Manual of clinical microbiology", pp.967~993 (2015), ASM Press
- Lee SA, "Global investigations of Fusobacterium nucleatum in human colorectal cancer", Front Oncol, 9, pp.566~ (2019)
- Kristensen LH, "Localised Fusobacterium necrophorum infections : a prospective laboratory-based Danish study", Eur J Clin Microbiol Infect Dis, 27, pp.733~739 (2008)
- Johannesen KM, "Lemierre’s syndrome : the forgotten disease", J Thromb Thrombolysis, 37, pp.246~248 (2014)
- Kristensen LH, "Fusobacterium necrophorum : from tonsillitis to Lemierre’s syndrome", Ugeskr Laeger, 171, pp.987~990 (2009)
- Bolstad AI, "Taxonomy, biology, and periodontal aspects of Fusobacterium nucleatum", Clin Microbiol Rev, 9, pp.55~71 (1996)
- Han YW, "Term stillbirth caused by oral Fusobacterium nucleatum", Obstet Gynecol, 115, pp.442~445 (2010)
- Goldberg EA, "Epidemiology and clinical outcomes of patients with Fusobacterium bacteraemia", Epidemiol Infect, 141, pp.325~329 (2013)
- Brennan CA, "Fusobacterium nucleatum–symbiont, opportunist and oncobacterium", Nat Rev Microbiol, 17, pp.156~166 (2019)
- Castellarin M, "Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma", Genome Res, 22, pp.299~306 (2012)
- Ohkusa T, "Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion : a possible pathogenic mechanism of ulcerative colitis", J Med Microbiol, 58, pp.535~545 (2009)
- CLSI, "Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard" (2018), Clinical and Laboratory Standards Institute
- Shilnikova II, "Evaluation of antibiotic susceptibility of Bacteroides, Prevotella and Fusobacterium species isolated from patients of the N. N. Blokhin Cancer Research Center, Moscow, Russia", Anaerobe, 31, pp.15~18 (2015)
- Brook I, "Antianaerobic antimicrobials : spectrum and susceptibility testing", Clin Microbiol Rev, 26, pp.526~546 (2013)
- Aldridge KE, "Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species", Antimicrob Agents Chemother, 45, pp.1238~1243 (2001)
- Teng LJ, "High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan", Antimicrob Agents Chemother, 46, pp.2908~2913 (2002)
- Brazier JS, "Fastidious anaerobe agar compared with Wilkins-Chalgren agar, brain heart infusion agar, and brucella agar for susceptibility testing of Fusobacterium species", Antimicrob Agents Chemother, 34, pp.2280~2282 (1990)
- Marchand-Austin A, "Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011", Anaerobe, 28, pp.120~125 (2014)
- Appelbaum PC, "Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers", Antimicrob Agents Chemother, 34, pp.1546~1550 (1990)
- CLSI, "Performance standards for antimicrobial susceptibility testing. Approved standard" (2020), Clinical and Laboratory Standards Institute
- Citron DM, "Update on the taxonomy and clinical aspects of the genus Fusobacterium", Clin Infect Dis, 35(S1), pp.S22~S27 (2002)
- Kostic AD, "Genomic analysis identifies association of Fusobacterium with colorectal carcinoma", Genome Res, 22, pp.292~298 (2012)
- Pett E, "Fusobacterium species infections : clinical spectrum and outcomes at a district general hospital", Infection, 42, pp.363~370 (2014)
- Epaulard O, "The changing pattern of Fusobacterium infections in humans : recent experience with Fusobacterium bacteraemia", Clin Microbiol Infect, 12, pp.178~181 (2006)
- Afra K, "Incidence, risk factors, and outcomes of Fusobacterium species bacteremia", BMC Infect Dis, 13, pp.264~ (2013)
- Nohrström E, "Clinical spectrum of bacteraemic Fusobacterium infections : from septic shock to nosocomial bacteraemia", Scand J Infect Dis, 43, pp.463~470 (2011)
- Candoni A, "Fusobacterium nucleatum : a rare cause of bacteremia in neutropenic patients with leukemia and lymphoma", Clin Microbiol Infect, 9, pp.1112~1115 (2003)
- Kwong TNY, "Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer", Gastroenterology, 155, pp.383~390 (2018)
- Brook I, "Fusobacterial head and neck infections in children", Int J Pediatr Otorhinolaryngol, 79, pp.953~958 (2015)
- Brook I, "Spectrum and treatment of anaerobic infections", J Infect Chemother, 22, pp.1~13 (2016)
- Johannesen KM, "Differences in mortality in Fusobacterium necrophorum and Fusobacterium nucleatum infections detected by culture and 16S rRNA gene sequencing", Eur J Clin Microbiol Infect Dis, 38, pp.75~80 (2019)
- Yang CC, "Characteristics and outcomes of Fusobacterium nucleatum bacteremia–a 6-year experience at a tertiary care hospital in northern Taiwan", Diagn Microbiol Infect Dis, 70, pp.167~174 (2011)
- Goldstein EJC, "Resistance trends in antimicrobial susceptibility of anaerobic bacteria, Part II", Clin Microbiol Newsl, 33, pp.9~15 (2011)
- 변정현, "Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species", Annals of Laboratory Medicine, 39(2), pp.190~199 (2019), 대한진단검사의학회[DOI]
- Ng LS, "Anaerobic bacteraemia revisited : species and susceptibilities", Ann Acad Med Singap, 44, pp.13~18 (2015)
- Conrads G, "Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum", Antimicrob Agents Chemother, 49, pp.434~437 (2005)
- Nord CE, "Mechanisms of beta-lactam resistance in anaerobic bacteria", Rev Infect Dis, 8(S5), pp.S543~S548 (1986)